TEL AVIV, Israel, November 26, 2012 /PRNewswire/ --
Israel-based medical device company Headway medical reports the successful completion of a series of clinical trials of Occiflex, its innovative therapeutic table designed to reduce chronic neck pain and headaches. The device will be available, starting in 2013, to physiotherapy clinics and rehabilitation centers throughout the world.
A revolutionary new device based on the principles of physiotherapy, Occiflex supports slow, repeated, and precise treatment for patients with muscle-dysfunction-related chronic pain. The Occiflex table mechanism allows physiotherapists to devise a manual mobilization file that is tailored to the needs of each patient, and, since it does not depend on the therapist's physical abilities, it can continue therapy for much longer than is standard and possible today. Plus, since each patient's therapy protocol is saved in a database, treatment can be reproduced precisely each time. The patient's file can be modified at any time, as conditions changes. The Occiflex treatment table improves the condition of the cervical joints, muscle, ligaments, and central nervous system control over the neck and head.
The Clinical Journal of Pain recently published a scientific article that describes the clinical trial conducted by Headway in the physiotherapy department of the Bnei Zion Medical Center in Haifa, Israel. The trial tested the advanced prototype developed by the company. Results indeed demonstrated a reduction of chronic neck pain in the patients and increased mobility.
According to Tamir Levital, CEO of Headway, "Occiflex will make the work of 50,000 physiotherapy and pain centers around the world more efficient and provide relief for the hundreds of millions who suffer from chronic neck pain and headaches. It will also save physiotherapists time and energy, and permit them to treat a number of patients simultaneously. The results of our trials show that Occiflex permits more precise, effective, repeated, and longer treatment than is possible today. We are very happy with the results of the trial and are getting ready to market Occiflex starting in 2013."
Headway, which got its start in the Misgav Venture Accelerator (owned by the Trendlines Group), was founded in 2006 by Dr. Yaron River, chief physician at the Neurology Department, Hillel Yaffe Medical Center, Hadera. The company has raised $1.5 million from private investors, the Misgav Venture Accelerator, and government R&D grants.
Ofir Shpigel Media and Public Relations
SOURCE Headway Medical